COVID‐19: A review of therapeutics under investigation

Crosby, James C.; Heimann, Matthew A.; Burleson, Samuel L.; Anzalone, Brendan; Swanson, Jonathan; Wallace, Douglas W.; Greene, Christopher J.

doi:10.1002/emp2.12081

Cited by 33 publications

(31 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inhibition of the vastly expressed pro-inflammatory factor nuclear factor kappa B (NF-κB) is one of the ways (59). Corticosteroids are recommended in the hyperinflammatory state related to acute respiratory distress syndrome (60) and have been used in severe COVID-19 patients with severe pneumonia (61). Corticosteroids are widely used in inflammatory conditions.…”

Section: Corticosteroidsmentioning

confidence: 99%

Pediatric Inflammatory Multisystem Syndrome and Rheumatic Diseases During SARS-CoV-2 Pandemic

2020

View full text Add to dashboard Cite

Globally, the coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), appeared to have a milder clinical course in children compared to adults. As severe forms of COVID-19 in adults included an aberrant systemic immune response, children with chronic systemic inflammatory diseases were cautiously followed. No evidence for a specific susceptibility was identified in this pediatric population. European and US Pediatricians started to notice cases of myocarditis, sharing some features with toxic shock syndrome, Kawasaki disease, and macrophage activation syndrome in otherwise healthy patients. Multisystem Inflammatory Syndrome in Children (MIS-C) and Pediatric Inflammatory Multisystem Syndrome (PIMS) have designated this new entity in the US and Europe, respectively. The spectrum of severity ranged from standard hospitalization to pediatric intensive care unit management. Most patients had a clinical history of exposure to COVID-19 patients and/or SARS-COV2 biological diagnosis. Clinical presentations include fever, cardiac involvement, gastro-intestinal symptoms, mucocutaneous manifestations, hematological features, or other organ dysfunctions. The temporal association between the pandemic peaks and outbreaks of PIMS seems to be in favor of a post-infectious, immune-mediated mechanism. Thus, SARS-CoV2 can rarely be associated with severe systemic inflammatory manifestations in previously healthy children differently from adults highlighting the specific need for COVID-19 research in the pediatric population.

show abstract

Section: Corticosteroidsmentioning

confidence: 99%

Pediatric Inflammatory Multisystem Syndrome and Rheumatic Diseases During SARS-CoV-2 Pandemic

2020

View full text Add to dashboard Cite

show abstract

“…However, no conclusive remarks on the efficacy of the therapy were made by the author. The result of another single ongoing clinical trial to determine the efficacy of anti-SARS-CoV-2 inactivated convalescent plasma remains to be seen 30 . Many clinical trials are currently being registered to observe effects of convalescent plasma in COVID-19 recovery (NCT04432013, NCT04388410, NCT04397757 etc).…”

Section: Types Of Treatments In Clinical Trialmentioning

confidence: 99%

Drug Repurposing for Prevention and Treatment of COVID-19: A Clinical Landscape

Hossain

Hami

Sawrav

et al. 2020

Discoveries (Craiova)

View full text Add to dashboard Cite

SARS-CoV-2, the novel coronavirus strain responsible for the current pandemic of COVID-19, has rendered the entire humanity suffering. Several months have passed since the pandemic has struck. However, the world is still looking for an effective treatment plan to battle the viral infection. The first vaccine just received emergency approval in December 2020 for use in USA and UK. These are excellent news, however, the worldwide distribution of such vaccine, the possibility of virus mutation and the lack of data regarding the long-term effects of such vaccines are a significant concern. In addition, although remdesivir was recently approved by the FDA to be used as a clinical drug against COVID-19, it hasn’t stood out yet as a proven form of therapeutics. Such inability to produce a novel therapy has caused enough inconveniences for the affected people worldwide. Repurposing the already available drugs to fight against the virus seems to be a reasonable option amidst such uncertainty. Given the vast collection of potential treatment candidates to be explored against COVID-19, there is a decent chance that a success in this regard will serve the intermediary purpose of clinically treating the infection until a COVID-19 vaccine is widely distributed worldwide and will be able to treat COVID-19 patients that do not adequately respond to vaccines. Such treatments may prove very useful in future coronavirus outbreaks too. Proper research into these repurposing treatments may yield a certain insight into the field of novel treatment production as well. This review study accumulates a relevant set of information about drugs and vaccines against COVID-19, in terms of their repurposing properties and the specific phases of clinical trials they are undergoing across the world. A potential timeline is also suggested to estimate when an effective result can be expected from the ongoing clinical trials for a better anticipation of the drug landscape. This study will hopefully help accelerate investment of resources into development and discovery of drugs and vaccines against the infection.

show abstract

“…The World Health Organization has declared the outbreak of COVID-19 to be a global pandemic [ 1 ]. Development of therapeutics and vaccines started early and remains a high priority [ 2 , 3 ]; however, no effective vaccine or drug treatment is currently available [ 4 ]. Moreover, negative social and economic consequences of broader shutdowns in many countries are already visible [ 5 ]; therefore, measures are being taken to revive social and economic life.…”

Section: Introductionmentioning

confidence: 99%

Motivations for Social Distancing and App Use as Complementary Measures to Combat the COVID-19 Pandemic: Quantitative Survey Study

Kaspar¹

2020

J Med Internet Res

120

127

View full text Add to dashboard Cite

Background The current COVID-19 pandemic is showing negative effects on human health as well as on social and economic life. It is a critical and challenging task to revive public life while minimizing the risk of infection. Reducing interactions between people by social distancing is an effective and prevalent measure to reduce the risk of infection and spread of the virus within a community. Current developments in several countries show that this measure can be technologically accompanied by mobile apps; meanwhile, privacy concerns are being intensively discussed. Objective The aim of this study was to examine central cognitive variables that may constitute people’s motivations for social distancing, using an app, and providing health-related data requested by two apps that differ in their direct utility for the individual user. The results may increase our understanding of people’s concerns and convictions, which can then be specifically addressed by public-oriented communication strategies and appropriate political decisions. Methods This study refers to the protection motivation theory, which is adaptable to both health-related and technology-related motivations. The concept of social trust was added. The quantitative survey included answers from 406 German-speaking participants who provided assessments of data security issues, trust components, and the processes of threat and coping appraisal related to the prevention of SARS-CoV-2 infection by social distancing. With respect to apps, one central focus was on the difference between a contact tracing app and a data donation app. Results Multiple regression analyses showed that the present model could explain 55% of the interindividual variance in the participants’ motivation for social distancing, 46% for using a contact tracing app, 42% for providing their own infection status to a contact tracing app, and 34% for using a data donation app. Several cognitive components of threat and coping appraisal were related to motivation measurements. Trust in other people’s social distancing behavior and general trust in official app providers also played important roles; however, the participants’ age and gender did not. Motivations for using and accepting a contact tracing app were higher than those for using and accepting a data donation app. Conclusions This study revealed some important cognitive factors that constitute people’s motivation for social distancing and using apps to combat the COVID-19 pandemic. Concrete implications for future research, public-oriented communication strategies, and appropriate political decisions were identified and are discussed.

show abstract

COVID‐19: A review of therapeutics under investigation

Cited by 33 publications

References 55 publications

Pediatric Inflammatory Multisystem Syndrome and Rheumatic Diseases During SARS-CoV-2 Pandemic

Pediatric Inflammatory Multisystem Syndrome and Rheumatic Diseases During SARS-CoV-2 Pandemic

Drug Repurposing for Prevention and Treatment of COVID-19: A Clinical Landscape

Motivations for Social Distancing and App Use as Complementary Measures to Combat the COVID-19 Pandemic: Quantitative Survey Study

Contact Info

Product

Resources

About